Lifu Ding Jiaonang (利福定胶囊)利福定胶囊
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 贵州大华制药有限公司Chinese legal name: 贵州大华制药有限公司
主要成分Active Ingredients
- 利福定Lifu Ding
药物知识说明
利福定是一种在国家药监局注册认定的药品。该药品含有利福定-f9b31286等成分。
该药品关联的活性成分包括：利福定Lifu Ding。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：贵州大华制药有限公司Chinese legal name: 贵州大华制药有限公司。
您可以探索含有相同成分的其他药品：利福定-f9b31286成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 利福定胶囊) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 利福定Lifu Ding.
Manufacturers recorded for this product: 贵州大华制药有限公司Chinese legal name: 贵州大华制药有限公司.
Explore other medicines containing the same ingredient: 利福定 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 利福定胶囊Recorded Chinese name: 利福定胶囊
- 剂型Dosage form: 胶囊剂Capsules
- 规格Specification: 0.15g0.15 g
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 贵州大华制药有限公司Chinese legal name: 贵州大华制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H52020535
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H52020535
Manufacturer
Chinese legal name: 贵州大华制药有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H52020535
生产企业
贵州大华制药有限公司(国产)
适应症
1.本品适用于各型肺结核和其他结核病，包括对多种抗结核药物已产生耐药性患者。 2.亦用于麻风病及敏感菌感染性皮肤病等。
用法用量
口服。 1.成人每日150～200mg，早晨空腹一次服用。 2.儿童按3～4mg/kg，一次服用。治疗肺结核病的疗程为1/2～1年。
不良反应
1.本品对胃肠道刺激轻微，较少出现恶心、呕吐、腹泻等。
2.长期使用可致肝、肾损害。
禁忌
对本品过敏者禁用。
注意事项
1.本品与利福平有交叉耐药性，故不适用于利福平治疗无效的病例。
2.用药期间应定期作血、尿常规和肝、肾功能检查，肝、肾功能不良者慎用。
3.治疗肺结核时，应与其他抗结核药物合并使用，以防止耐药菌的产生，并增加疗效。
贮藏
遮光，密封保存。
规格
0.15g
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.